Study To Evaluate The Safety, Tolerability, And Immunogenicity Of A Fifth Dose Of 6-Valent OSPA-Based Lyme Disease Vaccine, VLA15

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of A Fifth Dose Of 6-Valent OSPA-Based Lyme Disease Vaccine, VLA15, In Healthy Participants Greater Than Or Equal To 7 Years Of Age

Protocol # C4601016

Learn More

Principal Investigator(s)

Michael Parry, MD

Sponsor(s)
Pfizer, Inc.

Location

Our website uses cookies

This website uses cookies to give you the very best experience. Your continued use of this site is considered permission by you to use cookies in this manner. Please review our Privacy Policy and Terms of Use for more information about the data we collect and the types of cookies we use. Please note, if you link off our website to a 3rd party site of any kind, that website has its own terms and conditions.

ACCEPT AND CLOSE

Study To Evaluate The Safety, Tolerability, And Immunogenicity Of A Fifth Dose Of 6-Valent OSPA-Based Lyme Disease Vaccine, VLA15